GlassScriptPhysician profile
Amber Steinmetz
NPI 1780312470
$2,326.60
in general payments reported to CMS, 2019-2025
19 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $33.49 · 2024: $586 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278 · Education: $48.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.85 |
| Education | $48.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.76 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $523.74 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Harmony Biosciences LLC | $317.05 | 2025 | |
| Corcept Therapeutics | $142.38 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.73 | 2024-2025 | Caplyta |
| Alkermes, INC. | $93.86 | 2025 | Aristada, Lybalvi |
| Novo Nordisk INC | $85.75 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $85.21 | 2024-2025 | Auvelity, Sunosi |
| Mylan Specialty L.P. | $71.38 | 2024 | Yupelri |
| Indivior INC. | $60.18 | 2023-2025 | Sublocade |
| Glaxosmithkline, LLC. | $51.23 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $50.32 | 2024-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $42.86 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $39.45 | 2024 | |
| Medline Industries LP | $18.55 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.81 | 2025 | Xifaxan |
| Lundbeck LLC | $17.46 | 2025 | Rexulti |
| Amgen INC. | $16.41 | 2025 | Repatha |
| Kowa Pharmaceuticals America, INC. | $13.47 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Steinmetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.